Daily Ards Research Analysis
Analyzed 15 papers and selected 3 impactful papers.
Summary
Analyzed 15 papers and selected 3 impactful articles.
Selected Articles
1. NINJ1 plays a vital role in the release of neutrophil extracellular traps during acute lung injury.
Using patient neutrophils and mouse ALI models, the study identifies NINJ1 oligomerization as essential for NET release and lung injury. Genetic disruption of Ninj1 abolishes NETs, improves pulmonary function, and reduces mortality, with K45 and N60 residues critical for oligomerization. NINJ1 emerges as a druggable target for ALI/ARDS.
Impact: Reveals a previously unrecognized pore-forming mechanism driving NETosis in lung injury with direct therapeutic implications. Links human ARDS biology to actionable targets validated across multiple systems.
Clinical Implications: Pharmacologic inhibition of NINJ1 oligomerization could reduce NET-driven lung injury in ARDS. Biomarker development around NINJ1 expression may stratify patients for NET-targeted therapies.
Key Findings
- NINJ1 is highly expressed in pro-inflammatory neutrophil subpopulations in ALI by single-cell RNA-seq and hotspot analysis.
- NINJ1 oligomerization is essential for NET release in neutrophils from ARDS patients and ALI mice; K45 and N60 are critical residues.
- Neutrophil-specific Ninj1 ablation abolishes NET release, mitigates pulmonary dysfunction, and reduces ALI-related lethality.
Methodological Strengths
- Cross-species validation using human ARDS neutrophils and murine ALI models
- Mechanistic precision via identification of critical residues (K45, N60) governing NINJ1 oligomerization
Limitations
- Preclinical study without interventional pharmacology testing of NINJ1 inhibitors
- Quantitative clinical correlation and patient cohort size details are limited in the abstract
Future Directions: Develop and test selective NINJ1 oligomerization inhibitors; validate NINJ1 as a biomarker and therapeutic target in prospective ARDS cohorts and large-animal models.
Excessive neutrophil extracellular traps (NETs) formation is a significant contributor to acute lung injury (ALI), making its inhibition a novel therapeutic avenue to improve outcomes. In this study, we revealed that a novel pore-forming protein ninjurin-1 (NINJ1) was highly expressed in pro-inflammatory neutrophil subpopulations during ALI, using public single-cell RNA sequencing and hotspot analysis. Furthermore, we demonstrated that the NINJ1 oligomerization was essential for the NET release in neutrophils from both acute respiratory distress syndrome (ARDS) patients and ALI mice. Genetic ablation of Ninj1 in neutrophils abolished NET release, thereby attenuating pulmonary dysfunction and reducing ALI-related lethality. Mechanistically, we found that K45 and N60 are critical for NINJ1 oligomerization and subsequent NET release. In summary, our findings reveal a novel pore-forming protein-mediated mechanism for NET release and highlight NINJ1 as a potential therapeutic target for the treatment of ALI/ARDS.Schematic illustration. The novel pore-forming protein NINJ1 mediates the extrusion of NETs, thereby exacerbating pulmonary injury in ARDS/ALI. K45 and N60 are essential for NINJ1 oligomerization and subsequent NET release.
2. Dahuang-mudanpi decoction mitigates ALI/ARDS pulmonary inflammation via multi-target regulation of HMGB1.
In LPS-induced ALI mice, Dahuang-Mudanpi Decoction reduced lung injury and inflammatory cytokines. Paeonol likely limits HMGB1 nuclear translocation and release (via NLS1 interaction), while emodin suppresses extracellular HMGB1 function near its receptor-binding region, indicating complementary HMGB1-targeting actions.
Impact: Proposes a mechanistically coherent, multi-target HMGB1 modulation strategy using defined phytochemicals, expanding therapeutic avenues for ALI/ARDS beyond single-target inhibitors.
Clinical Implications: Although preclinical, the complementary HMGB1 actions of paeonol and emodin suggest a rational combination approach to dampen sterile lung inflammation. Standardization and pharmacokinetics will be prerequisites for translation.
Key Findings
- DMD reduced lung injury indices and inflammatory cytokines (IL-1β, TNF-α, IL-6, HMGB1) in LPS-induced ALI mice.
- Paeonol is predicted to interact with HMGB1 NLS1, limiting nuclear translocation and extracellular release.
- Emodin is predicted to bind near HMGB1’s receptor-binding region, suppressing extracellular HMGB1 pro-inflammatory activity.
Methodological Strengths
- In vivo efficacy assessment with quantitative cytokine profiling and histopathology
- Component-level mechanistic dissection supported by HPLC quantification and molecular docking
Limitations
- Predominantly a single-model murine study; lack of diverse injury models and species
- Docking provides supportive but not definitive binding evidence; no direct biophysical validation
Future Directions: Validate findings in additional ALI/ARDS models and species; perform biophysical binding assays and pharmacokinetics; pilot safety studies of standardized formulations.
BACKGROUND: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe inflammatory conditions with high mortality and limited treatment options. Targeting pulmonary inflammation is a critical strategy for improving clinical outcomes. This study was performed to investigate the therapeutic effects and underlying mechanisms of Dahuang-Mudanpi Decoction (DMD), specifically focusing on its active ingredients, paeonol (PAE) and emodin (EMO), and their regulatory role in high mobility group box 1 (HMGB1)-mediated inflammation in ALI/ARDS. METHODS: The therapeutic efficacy of DMD was evaluated using a lipopolysaccharide (LPS)-induced ALI mouse model (n = 8 per group for the DMD dose-screening experiment and n = 6 per group for the component-comparison experiment). High-performance liquid chromatography (HPLC) was employed to quantify the active compounds within DMD. The protective effects were comprehensively assessed by analyzing body weight changes, lung wet/dry (W/D) ratios, and histopathological lung injury scores. Additionally, systemic and localized inflammatory responses were evaluated by measuring hematological parameters and the levels of key inflammatory cytokines, including interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and HMGB1. Data were analyzed using one-way analysis of variance (ANOVA) or nonparametric tests, as appropriate. RESULTS: DMD administration significantly mitigated LPS-induced pulmonary inflammation and attenuated lung injury in the mouse model. Mechanistic evaluations revealed distinct, complementary roles for DMD's active components, with molecular docking providing supportive structural evidence rather than definitive proof of direct molecular binding. Specifically, PAE was predicted to interact with the first nuclear localization signal (NLS1) region of HMGB1 (Vina score: -4.7 kcal/mol), which corresponded to its observed ability to effectively inhibit the nuclear translocation of HMGB1 and reduce its extracellular release. Conversely, EMO was predicted to bind near the receptor-binding region of HMGB1 (Vina score: -6.3 kcal/mol), suppressing the pro-inflammatory function of extracellular HMGB1. CONCLUSION: These findings demonstrate the multi-target regulatory effects of DMD in mitigating ALI-associated inflammation, highlighting PAE and EMO as promising therapeutic agents for ALI/ARDS. The mechanistic insights provide novel perspectives on HMGB1-targeted treatments, suggesting that further optimization of this compound combination could yield advanced therapeutic strategies for severe pulmonary inflammation.
3. The safety and efficacy of human umbilical cord mesenchymal stem cell for acute respiratory distress syndrome: an open-label and multicenter phase 1 clinical trial.
A multicenter, open-label phase I dose-escalation trial (n=12) of hUC-MSCs in mild-to-moderate ARDS demonstrated safety and tolerability, with a promising efficacy signal at the middle dose. Exploratory immunologic markers were collected to inform future randomized trials.
Impact: Provides contemporary, multicenter phase I safety data and a dose signal for cell therapy in ARDS, a condition lacking disease-modifying treatments.
Clinical Implications: Supports feasibility and safety of hUC-MSC infusion in ARDS, justifying phase II/III RCTs and dose optimization. May guide selection of immunologic endpoints for future trials.
Key Findings
- Open-label multicenter phase I dose-escalation (3+3) enrolled 12 ARDS patients across three dose levels.
- Single intravenous hUC-MSC infusion was safe and well tolerated over 28 days.
- A promising efficacy signal was observed at the middle dose, informing future randomized trial design.
Methodological Strengths
- Prospective multicenter dose-escalation design with standardized 28-day assessments
- Integration of exploratory immunologic biomarkers to support mechanistic interpretation
Limitations
- Open-label, small sample (n=12) phase I without control group limits efficacy inference
- Abstract lacks detailed quantitative outcomes and adverse event rates
Future Directions: Conduct adequately powered, placebo-controlled RCTs to confirm efficacy and refine dosing; incorporate standardized clinical and immunologic endpoints.
TRIAL DESIGN: Acute Respiratory Distress Syndrome (ARDS) remains a life-threatening critical illness with high mortality and limited specific therapies. This open-label, multicenter Phase I clinical trial aimed to evaluate the safety, tolerability, and preliminary efficacy of allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs, BC-U001) in patients with mild-to-moderate ARDS. A total of 12 eligible patients were enrolled into three dose groups following a "3 + 3" dose-escalation design from 2019 to 2024. METHODS: All patients received standard ARDS care plus a single intravenous infusion of BC-U001, with 28-day follow-up to assess safety and efficacy as well as exploratory immunological indicators (immunoglobulins, inflammatory cytokines, lymphocyte subsets). RESULTS: Baseline characteristics were balanced across groups except for more severe baseline lung injury in high dose patients ( CONCLUSIONS: These findings demonstrate that hUC-MSCs are safe and well-tolerated in mild-to-moderate ARDS patients, with the middle dose showing promising therapeutic effects. This trial provides critical data to support the design of future large-scale, randomized controlled trials to confirm the efficacy of hUC-MSCs for ARDS.